Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (11 quarters reported)
$375M in Q4 2023 → $581M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Tango Therapeutics Inc | 6.6% | Added 509% | 1,223,019 | $38.2M |
| Abivax Sa | 6.5% | Trimmed 9.6% | 283,657 | $37.8M |
| Revolution Medicines Inc | 5.2% | Trimmed 43% | 159,943 | $30M |
| Erasca Inc | 4.9% | Added 553% | 1,565,913 | $28.7M |
| Tyra Biosciences Inc | 3.5% | Added 228% | 632,754 | $20.2M |
| Dianthus Therapeutics Inc | 3.4% | Added 135% | 200,851 | $19.6M |
| Enliven Therapeutics Inc | 3.0% | Trimmed 4.5% | 346,914 | $17.6M |
| Mineralys Therapeutics Inc | 2.8% | Added 13% | 602,686 | $16.3M |
| Biohaven Ltd | 2.7% | Trimmed 33% | 1,064,200 | $15.8M |
| Surrozen Inc | 2.4% | Added 208% | 602,798 | $13.8M |
| KP Kiniksa Pharmaceuticals Intl | 2.3% | New | 209,234 | $13.4M |
| SR Scholar Rock Hldg Corp | 2.3% | Trimmed 77% | 239,146 | $13.2M |
| Alkermes PLC | 2.2% | Added 208% | 248,015 | $13M |
| First Tracks Biotherapeutics | 2.2% | New | 622,723 | $12.5M |
| PP Praxis Precision Medicines I | 2.1% | Trimmed 34% | 37,243 | $12.5M |
| Roivant Sciences Ltd | 2.1% | Trimmed 9.7% | 348,408 | $12.3M |
| Bioage Labs Inc | 2.0% | Added 37% | 464,171 | $11.4M |
| Cg Oncology Inc | 2.0% | Trimmed 23% | 159,349 | $11.3M |
| Oruka Therapeutics Inc | 1.9% | New | 116,461 | $11.1M |
| Immunovant Inc | 1.8% | Trimmed 63% | 276,527 | $10.7M |
| Celcuity Inc | 1.8% | Added 64% | 98,203 | $10.3M |
| Relmada Therapeutics Inc | 1.7% | Added 144% | 1,460,093 | $10.1M |
| Climb Bio Inc | 1.7% | New | 742,745 | $9.69M |
| Spyre Therapeutics Inc | 1.6% | Trimmed 36% | 106,926 | $9.49M |
| Zura Bio Ltd | 1.4% | Added 82% | 1,368,215 | $8.07M |
| Inflarx Nv | 1.2% | New | 3,228,255 | $7.23M |
| Amylyx Pharmaceuticals Inc | 1.2% | Trimmed 43% | 384,304 | $6.9M |
| CT Celldex Therapeutics Inc New | 1.1% | Trimmed 30% | 178,412 | $6.64M |
| Ovid Therapeutics Inc | 1.1% | New | 2,417,283 | $6.5M |
| Equillium Inc | 1.1% | New | 2,016,607 | $6.45M |
| Definium Therapeutics Inc | 1.1% | Trimmed 58% | 137,124 | $6.45M |
| Cytokinetics Inc | 1.1% | Trimmed 42% | 75,603 | $6.44M |
| Damora Therapeutics Inc | 1.0% | New | 216,194 | $5.62M |
| Inventiva Sa | 0.9% | New | 1,426,320 | $5.39M |
| Century Therapeutics Inc | 0.9% | New | 2,146,182 | $5.26M |
| Aura Biosciences Inc | 0.9% | New | 714,280 | $5.07M |
| Eyepoint Inc | 0.8% | Trimmed 58% | 338,471 | $4.84M |
| Assembly Biosciences Inc | 0.8% | Trimmed 8.1% | 170,378 | $4.68M |
| Whitehawk Therapeutics Inc | 0.8% | Added 8.7% | 1,021,037 | $4.68M |
| Xenon Pharmaceuticals Inc | 0.8% | Trimmed 46% | 76,075 | $4.59M |
| UN Uniqure Nv | 0.7% | Added 13% | 88,115 | $4.06M |
| Compass Pathways PLC | 0.7% | New | 284,769 | $4.03M |
| AP Avalyn Pharmaceuticals Inc | 0.7% | New | 118,000 | $3.88M |
| Maplight Therapeutics Inc | 0.7% | Added 6.9% | 106,906 | $3.83M |
| Alumis Inc | 0.7% | Trimmed 41% | 135,736 | $3.82M |
| Axsome Therapeutics Inc. | 0.6% | New | 15,375 | $3.76M |
| Monte Rosa Therapeutics Inc | 0.6% | New | 153,544 | $3.72M |
| Acadia Pharmaceuticals Inc | 0.6% | Trimmed 41% | 143,167 | $3.62M |
| Solid Biosciences Inc | 0.6% | Added 84% | 358,780 | $3.58M |
| Personalis Inc | 0.6% | New | 247,783 | $3.32M |
| Crescent Biopharma Inc. | 0.6% | New | 182,382 | $3.28M |
| AP Arrowhead Pharmaceuticals In | 0.6% | New | 39,198 | $3.2M |
| Kodiak Sciences Inc | 0.5% | New | 75,872 | $2.96M |
| Pharvaris N V | 0.5% | Trimmed 6.6% | 80,907 | $2.8M |
| Monopar Therapeutics Inc | 0.5% | New | 30,125 | $2.79M |
| Rapport Therapeutics Inc | 0.5% | New | 66,582 | $2.77M |
| NP Newamsterdam Pharma Company | 0.5% | Trimmed 57% | 77,589 | $2.63M |
| Sionna Therapeutics Inc | 0.5% | Added 63% | 59,426 | $2.61M |
| Arcutis Biotherapeutics Inc | 0.4% | Trimmed 76% | 98,945 | $2.59M |
| C4 Therapeutics Inc | 0.4% | Added 16% | 523,648 | $2.45M |
Showing top 60 of 84 positions.
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SR Scholar Rock Hldg Corp | Trimmed | −796,350 | −$43.8M | 2.3% |
| Tango Therapeutics Inc | Added | +1,022,100 | +$32M | 6.6% |
| Syndax Pharmaceuticals Inc | Exited | −1,215,743 | −$28.4M | — |
| Erasca Inc | Added | +1,326,052 | +$24.3M | 4.9% |
| Revolution Medicines Inc | Trimmed | −121,689 | −$22.8M | 5.2% |
| Immunovant Inc | Trimmed | −469,967 | −$18.1M | 1.8% |
| Mbx Biosciences Inc | Exited | −499,469 | −$14.9M | — |
| Tyra Biosciences Inc | Added | +439,577 | +$14M | 3.5% |
| KP Kiniksa Pharmaceuticals Intl | New | +209,234 | +$13.4M | 2.3% |
| First Tracks Biotherapeutics | New | +622,723 | +$12.5M | 2.2% |
Showing the 10 largest of 115 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Centessa Pharmaceuticals PLC | Exited | −1,154,114 | −$28.9M | — |
| Twist Bioscience Corp | Trimmed | −475,245 | −$22.6M | 0.4% |
| Arcellx Inc | Exited | −332,860 | −$21.7M | — |
| Revolution Medicines Inc | Added | +219,600 | +$21.4M | 5.3% |
| Terns Pharmaceuticals Inc | Exited | −429,198 | −$17.3M | — |
| Roivant Sciences Ltd | Trimmed | −580,898 | −$16.1M | 2.1% |
| Enliven Therapeutics Inc | New | +363,438 | +$14.2M | 2.8% |
| Cg Oncology Inc | New | +205,622 | +$13.9M | 2.7% |
| Biohaven Ltd | New | +1,594,491 | +$13.5M | 2.6% |
| Mbx Biosciences Inc | Added | +420,916 | +$12.6M | 2.9% |
Showing the 10 largest of 118 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Roivant Sciences Ltd | Trimmed | −3,230,489 | −$70.1M | 3.6% |
| Abivax Sa | Added | +225,510 | +$30.4M | 9.1% |
| Immunovant Inc | Trimmed | −944,621 | −$24M | 2.8% |
| Denali Therapeutics Inc | Trimmed | −1,315,601 | −$21.7M | 1.2% |
| Arcellx Inc | Added | +321,484 | +$21M | 3.7% |
| Twist Bioscience Corp | New | +518,355 | +$16.4M | 2.8% |
| Wave Life Sciences Ltd | Exited | −2,110,152 | −$15.4M | — |
| Structure Therapeutics Inc | Added | +221,738 | +$15.4M | 4.2% |
| Biohaven Ltd | Exited | −1,017,311 | −$15.3M | — |
| Cidara Therapeutics Inc | Exited | −152,325 | −$14.6M | — |
Showing the 10 largest of 119 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Roivant Sciences Ltd | Added | +3,595,406 | +$54.4M | 12.7% |
| Madrigal Pharmaceuticals Inc | Trimmed | −44,487 | −$20.4M | 0.8% |
| Mineralys Therapeutics Inc | Trimmed | −473,474 | −$18M | 1.2% |
| Arcellx Inc | Trimmed | −190,076 | −$15.6M | 0.2% |
| Syndax Pharmaceuticals Inc | Trimmed | −1,006,429 | −$15.5M | 4.2% |
| Denali Therapeutics Inc | Added | +1,026,744 | +$14.9M | 5.0% |
| Centessa Pharmaceuticals PLC | Trimmed | −610,287 | −$14.8M | 3.2% |
| Merus N V | Exited | −266,094 | −$14M | — |
| Biohaven Ltd | Added | +842,557 | +$12.6M | 3.1% |
| Cidara Therapeutics Inc | Trimmed | −114,449 | −$11M | 2.9% |
Showing the 10 largest of 100 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Roivant Sciences Ltd | Trimmed | −1,977,079 | −$22.3M | 2.2% |
| Cidara Therapeutics Inc | New | +266,774 | +$13M | 4.2% |
| Revolution Medicines Inc | Exited | −318,782 | −$11.3M | — |
| Nuvalent Inc | Trimmed | −130,573 | −$9.96M | 1.5% |
| Legend Biotech Corp | New | +270,144 | +$9.59M | 3.1% |
| Xenon Pharmaceuticals Inc | Exited | −274,633 | −$9.21M | — |
| Rhythm Pharmaceuticals Inc | Added | +142,936 | +$9.03M | 3.6% |
| Centessa Pharmaceuticals PLC | Added | +672,337 | +$8.83M | 5.3% |
| Mineralys Therapeutics Inc | New | +631,586 | +$8.55M | 2.7% |
| Geron Corp | Added | +5,688,937 | +$8.02M | 3.0% |
Showing the 10 largest of 81 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Arcellx Inc | New | +273,774 | +$18M | 5.7% |
| CP Crinetics Pharmaceuticals In | Exited | −317,060 | −$16.2M | — |
| Syndax Pharmaceuticals Inc | Trimmed | −1,274,007 | −$15.7M | 6.3% |
| Madrigal Pharmaceuticals Inc | New | +40,936 | +$13.6M | 4.3% |
| Incyte Corp | Exited | −193,623 | −$13.4M | — |
| SR Scholar Rock Hldg Corp | Added | +399,905 | +$12.9M | 5.8% |
| Merus N V | Trimmed | −268,056 | −$11.3M | 4.7% |
| PP Praxis Precision Medicines I | Exited | −134,178 | −$10.3M | — |
| Bristol-myers Squibb Co | Exited | −166,068 | −$9.39M | — |
| Rhythm Pharmaceuticals Inc | Trimmed | −174,200 | −$9.23M | 0.6% |
Showing the 10 largest of 84 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Arcutis Biotherapeutics Inc | Trimmed | −1,277,352 | −$17.8M | 1.7% |
| Amicus Therapeutics Inc | Exited | −1,481,809 | −$15.8M | — |
| Syndax Pharmaceuticals Inc | Added | +1,141,410 | +$15.1M | 9.5% |
| Xenon Pharmaceuticals Inc | New | +375,845 | +$14.7M | 3.7% |
| Applied Therapeutics Inc | Exited | −1,554,586 | −$13.2M | — |
| Nuvalent Inc | New | +145,234 | +$11.4M | 2.8% |
| Immunovant Inc | Added | +447,507 | +$11.1M | 6.9% |
| Alkermes PLC | Added | +368,050 | +$10.6M | 3.0% |
| Autolus Therapeutics PLC | Exited | −2,616,602 | −$9.5M | — |
| Centessa Pharmaceuticals PLC | Added | +558,302 | +$9.35M | 2.7% |
Showing the 10 largest of 79 changes.
quarter ended September 30, 2024 · filed November 13, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Arcellx Inc | Trimmed | −220,633 | −$18.4M | 1.5% |
| CP Crinetics Pharmaceuticals In | Trimmed | −337,280 | −$17.2M | 3.3% |
| Bristol-myers Squibb Co | New | +275,303 | +$14.2M | 4.3% |
| IH Immunocore Hldgs PLC | Exited | −339,351 | −$11.5M | — |
| Merck & Co Inc | Exited | −81,508 | −$10.2M | — |
| Immunovant Inc | Trimmed | −340,878 | −$9.72M | 5.7% |
| Gsk PLC | Exited | −245,933 | −$9.47M | — |
| Kalvista Pharmaceuticals Inc | Exited | −736,765 | −$8.68M | — |
| Incyte Corp | New | +129,490 | +$8.56M | 2.6% |
| PP Praxis Precision Medicines I | Added | +144,775 | +$8.33M | 3.0% |
Showing the 10 largest of 65 changes.
Loading...
